This Viewpoint describes the rapid spread of use of high-intensity focused ultrasound ablation as a treatment for prostate cancer and calls for establishment of a registry to better assess the efficacy and safety of this approach.
This ecologic study examines changes in prostate cancer incidence and PSA screening rate among men 50 years and older in relation to US Preventive Services Task Force screening recommendations using registry and survey data.
This observational study examines prostate-specific antigen screening data from the National Health Interview Survey from 2000-2013 to determine the prevalence and determinants of screening before and after the 2012 US Preventive Services Task Force recommendations against such screening.
A 59-year-old white man was found to have an enlarged prostate without nodules after undergoing a digital rectal examination. He had no family history of prostate cancer. His prostate-specific antigen (PSA) levels slowly increased over the past dacade. How do you interpret the results of his PSA history?
This study uses long-term follow-up data from a randomized trial comparing radiation therapy with vs without androgen deprivation therapy for unfavorable-risk prostate cancer to compare survival and cause-specific mortality by severity of comorbidity.
This analysis uses data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) national registry to report on changes in the types of treatment patients with low-risk prostate cancer received from 1990 through 2013.
This cohort study reports that targeted magnetic resonance/ultrasound fusion biopsy, compared with standard extended-sextant ultrasound-guided biopsy, was associated with increased detection of high-risk prostate cancer and decreased detection of low-risk prostate cancer among men undergoing biopsy for suspected prostate cancer.
This Guide to Statistics and Methods describes how a decision curve analysis can be used to evaluate the benefits of a diagnostic test, such as 3 prostate biopsy strategies.
In a randomized trial testing the efficacy of tadalafil with radiotherapy to treat prostate cancer, Pisansky and coauthors found that compared with placebo, 24 weeks of tadalafil daily did not result in in improved spontaneous, off-drug erectile function.